Search

Your search keyword '"Willison, Alice"' showing total 50 results
Start Over Author "Willison, Alice" Publication Year Range Last 50 years
50 results on '"Willison, Alice"'

1. Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort

Author

Quint, Paula, Schroeter, Christina B., Kohle, Felix, Öztürk, Menekse, Meisel, Andreas, Tamburrino, Giuliano, Mausberg, Anne K., Szepanowski, Fabian, Afzali, Ali Maisam, Fischer, Katinka, Nelke, Christopher, Räuber, Saskia, Voth, Jan, Masanneck, Lars, Willison, Alice, Vogelsang, Anna, Hemmer, Bernhard, Berthele, Achim, Schroeter, Michael, Hartung, Hans-Peter, Pawlitzki, Marc, Schreiber, Stefanie, Stettner, Mark, Maus, Uwe, Meuth, Sven G., Stascheit, Frauke, and Ruck, Tobias

Published
2024
Full Text
View/download PDF

2. Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis

Author

Schroeter, Christina B., Nelke, Christopher, Stascheit, Frauke, Huntemann, Niklas, Preusse, Corinna, Dobelmann, Vera, Theissen, Lukas, Pawlitzki, Marc, Räuber, Saskia, Willison, Alice, Vogelsang, Anna, Marina, Adela Della, Hartung, Hans-Peter, Melzer, Nico, Konen, Felix F., Skripuletz, Thomas, Hentschel, Andreas, König, Simone, Schweizer, Michaela, Stühler, Kai, Poschmann, Gereon, Roos, Andreas, Stenzel, Werner, Meisel, Andreas, Meuth, Sven G., and Ruck, Tobias

Published
2024
Full Text
View/download PDF

3. Review and meta-analysis of neuropsychological findings in autoimmune limbic encephalitis with autoantibodies against LGI1, CASPR2, and GAD65 and their response to immunotherapy

Author

Mueller, Christoph, Elben, Saskia, Day, Gregory S., Alves, Pedro, Hebert, Julien, Tang-Wai, David F., Holtmann, Olga, Iorio, Raffaele, Perani, Daniela, Titulaer, Maarten J., Hansen, Niels, Bartsch, Thorsten, Johnen, Andreas, Illes, Zsolt, Borm, Leah, Willison, Alice G., Wiendl, Heinz, Meuth, Sven G., Kovac, Stjepana, Bölte, Jens, and Melzer, Nico

Published
2023
Full Text
View/download PDF

5. Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

Author

Regner-Nelke, Liesa, Pawlitzki, Marc, Willison, Alice, Rolfes, Leoni, Oezalp, Sinem-Hilal, Nelke, Christopher, Kölsche, Tristan, Korsen, Melanie, Grothe, Matthias, Groppa, Sergiu, Luessi, Felix, Engel, Sinah, Nelles, Gereon, Bonmann, Eckhard, Roick, Holger, Friedrich, Anke, Knorn, Philipp, Landefeld, Harald, Biro, Zoltan, Ernst, Michael, Bayas, Antonios, Menacher, Martina, Akgün, Katja, Kleinschnitz, Christoph, Ruck, Tobias, Ziemssen, Tjalf, Pul, Refik, and Meuth, Sven G.

Published
2022
Full Text
View/download PDF

8. The Use of Nitrosative Stress Molecules as Potential Diagnostic Biomarkers in Multiple Sclerosis

Author

Räuber, Saskia, primary, Förster, Moritz, additional, Schüller, Julia, additional, Willison, Alice, additional, Golombeck, Kristin S., additional, Schroeter, Christina B., additional, Oeztuerk, Menekse, additional, Jansen, Robin, additional, Huntemann, Niklas, additional, Nelke, Christopher, additional, Korsen, Melanie, additional, Fischer, Katinka, additional, Kerkhoff, Ruth, additional, Leven, Yana, additional, Kirschner, Patricia, additional, Kölsche, Tristan, additional, Nikolov, Petyo, additional, Mehsin, Mohammed, additional, Marae, Gelenar, additional, Kokott, Alma, additional, Pul, Duygu, additional, Schulten, Julius, additional, Vogel, Niklas, additional, Ingwersen, Jens, additional, Ruck, Tobias, additional, Pawlitzki, Marc, additional, Meuth, Sven G., additional, Melzer, Nico, additional, and Kremer, David, additional

Published
2024
Full Text
View/download PDF

9. Ofatumumab-induced severe reactivation of psoriasis in a patient with multiple sclerosis.

Author

Kölsche, Tristan, Willison, Alice Grizzel, Meuth, Sven G, Pawlitzki, Marc, Horbrügger, Marc, Skripuletz, Thomas, Meller, Stephan, and Pfeuffer, Steffen

Subjects
*REGULATORY B cells, *DIMETHYL fumarate, *MAGNETIC resonance imaging, *SYMPTOMS, *CERVICAL cord, *PSORIATIC arthritis, *AUTOIMMUNE diseases
Abstract

This letter discusses the case of a 58-year-old woman with relapsing remitting multiple sclerosis (RRMS) who experienced a severe exacerbation of psoriasis after being treated with ofatumumab, an anti-CD20 monoclonal antibody. Despite discontinuing ofatumumab and trying various treatments, her psoriasis continued to worsen. Eventually, she was treated with secukinumab, a fully human monoclonal IL-17A antibody approved for psoriasis, which resulted in significant improvement. The letter highlights the potential risk of worsening psoriasis with B-cell-depleting therapies in RRMS patients and suggests that anti-IL17 antibodies may be a good alternative treatment option. [Extracted from the article]

Published
2024
Full Text
View/download PDF

12. Eculizumab treatment alters the proteometabolome beyond the inhibiton of complement

Author

Nelke, Christopher, primary, Schroeter, Christina B., additional, Stascheit, Frauke, additional, Huntemann, Niklas, additional, Pawlitzki, Marc, additional, Willison, Alice G., additional, Räuber, Saskia, additional, Melzer, Nico, additional, Distler, Ute, additional, Tenzer, Stefan, additional, Stühler, Kai, additional, Roos, Andreas, additional, Meisel, Andreas, additional, Meuth, Sven G., additional, and Ruck, Tobias, additional

Published
2023
Full Text
View/download PDF

13. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab

Author

Pfeuffer, Steffen, primary, Rolfes, Leoni, additional, Ingwersen, Jens, additional, Pul, Refik, additional, Kleinschnitz, Konstanze, additional, Korsen, Melanie, additional, Räuber, Saskia, additional, Ruck, Tobias, additional, Schieferdecker, Simon, additional, Willison, Alice Grizzel, additional, Aktas, Orhan, additional, Kleinschnitz, Christoph, additional, Hartung, Hans-Peter, additional, Kappos, Ludwig, additional, and Meuth, Sven G., additional

Published
2023
Full Text
View/download PDF

14. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab

Author

Räuber, Saskia, primary, Willison, Alice, additional, Korsen, Melanie, additional, Kölsche, Tristan, additional, Golombeck, Kristin S., additional, Plaack, Benedikt, additional, Schüller, Julia, additional, Huntemann, Niklas, additional, Rolfes, Leoni, additional, Schroeter, Christina B., additional, Nelke, Christopher, additional, Regner-Nelke, Liesa, additional, Förster, Moritz, additional, Ringelstein, Marius, additional, Barnett, Michael Harry, additional, Hartung, Hans-Peter, additional, Aktas, Orhan, additional, Albrecht, Philipp, additional, Ruck, Tobias, additional, Melzer, Nico, additional, Meuth, Sven G., additional, and Kremer, David, additional

Published
2022
Full Text
View/download PDF

15. Degenerative cervical myelopathy education in UK medical schools: a national cross-sectional survey of medical students

Author

Brannigan, Jamie F. M., primary, Davies, Benjamin M., additional, Stewart, Max, additional, Smith, Sam, additional, Willison, Alice, additional, Ahmed, Shahzaib, additional, Sadler, Iwan, additional, Sarewitz, Ellen, additional, Francis, Jibin, additional, Stacpoole, Sybil R. L., additional, Kotter, Mark R. N., additional, and Mowforth, Oliver D., additional

Published
2022
Full Text
View/download PDF

16. Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies

Author

Masanneck, Lars, primary, Rolfes, Leoni, additional, Regner-Nelke, Liesa, additional, Willison, Alice, additional, Räuber, Saskia, additional, Steffen, Falk, additional, Bittner, Stefan, additional, Zipp, Frauke, additional, Albrecht, Philipp, additional, Ruck, Tobias, additional, Hartung, Hans-Peter, additional, Meuth, Sven G., additional, and Pawlitzki, Marc, additional

Published
2022
Full Text
View/download PDF

17. Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity

Author

Ruck, Tobias, primary, Barman, Sumanta, additional, Schulte-Mecklenbeck, Andreas, additional, Pfeuffer, Steffen, additional, Steffen, Falk, additional, Nelke, Christopher, additional, Schroeter, Christina B., additional, Willison, Alice, additional, Heming, Michael, additional, Müntefering, Thomas, additional, Melzer, Nico, additional, Krämer, Julia, additional, Lindner, Maren, additional, Riepenhausen, Marianne, additional, Gross, Catharina C., additional, Klotz, Luisa, additional, Bittner, Stefan, additional, Muraro, Paolo A., additional, Schneider-Hohendorf, Tilman, additional, Schwab, Nicholas, additional, Meyer zu Hörste, Gerd, additional, Goebels, Norbert, additional, Meuth, Sven G., additional, and Wiendl, Heinz, additional

Published
2022
Full Text
View/download PDF

20. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy:Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM

Author

Mowforth, Oliver D, Khan, Danyal Z, Wong, Mei Yin, Pickering, George A E, Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, Hazenbiller, Olesja, Sarewitz, Ellen, Sadler, Iwan, Gronlund, Toto, Tetreault, Lindsay, Harrop, James S, Aarabi, Bizhan, Rahimi-Movaghar, Vafa, Kurpad, Shekar N, Guest, James D, Wilson, Jefferson R, Kwon, Brian K, Fehlings, Michael G, McNair, Angus G K, Davies, Benjamin M, and Kotter, Mark R N

Subjects
spondylosis, surveys and questionnaires, Orthopedics and Sports Medicine, Surgery, Neurology (clinical), cervical vertebrae, spinal osteophytosis, spinal cord diseases
Abstract

Study Design Survey. Introduction AO Spine Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy (AO Spine RECODE-DCM) is an international initiative that aims to accelerate knowledge discovery and improve outcomes by developing a consensus framework for research. This includes defining the top research priorities, an index term and a minimum data set (core outcome set and core data elements set – core outcome set (COS)/core data elements (CDE)). Objective To describe how perspectives were gathered and report the detailed sampling characteristics. Methods A two-stage, electronic survey was used to gather and seek initial consensus. Perspectives were sought from spinal surgeons, other healthcare professionals and people with degenerative cervical myelopathy (DCM). Participants were allocated to one of two parallel streams: (1) priority setting or (2) minimum dataset. An email campaign was developed to advertise the survey to relevant global stakeholder individuals and organisations. People with DCM were recruited using the international DCM charity Myelopathy.org and its social media channels. A network of global partners was recruited to act as project ambassadors. Data from Google Analytics, MailChimp and Calibrum helped optimise survey dissemination. Results Survey engagement was high amongst the three stakeholder groups: 208 people with DCM, 389 spinal surgeons and 157 other healthcare professionals. Individuals from 76 different countries participated; the United States, United Kingdom and Canada were the most common countries of participants. Conclusion AO Spine RECODE-DCM recruited a diverse and sufficient number of participants for an international PSP and COS/CDE process. Whilst PSP and COS/CDE have been undertaken in other fields, to our knowledge, this is the first time they have been combined in one process.

Published
2021

21. Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis

Author

Vogelsang, Anna, primary, Eichler, Susann, additional, Huntemann, Niklas, additional, Masanneck, Lars, additional, Böhnlein, Hannes, additional, Schüngel, Lisa, additional, Willison, Alice, additional, Loser, Karin, additional, Nieswandt, Bernhard, additional, Kehrel, Beate E., additional, Zarbock, Alexander, additional, Göbel, Kerstin, additional, and Meuth, Sven G., additional

Published
2021
Full Text
View/download PDF

28. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy: Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM

Author

Davies, Benjamin M., Kwon, Brian K., Fehlings, Michael G., Kotter, Mark R. N., Mowforth, Oliver D., Khan, Danyal Z, Wong, Mei Yin, Pickering, George A. E., Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, Hazenbiller, Olesja, Sarewitz, Ellen, Sadler, Iwan, Gronlund, Toto, Tetreault, Lindsay, Harrop, James S., Aarabi, Bizhan, Rahimi-Movaghar, Vafa, Kurpad, Shekar N, Guest, James D., Wilson, Jefferson R., Kwon, Brian K., Fehlings, Michael G., McNair, Angus G.K., Davies, Benjamin M., and Kotter, Mark R.N.

Abstract

Study Design Survey.Introduction AO Spine Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy (AO Spine RECODE-DCM) is an international initiative that aims to accelerate knowledge discovery and improve outcomes by developing a consensus framework for research. This includes defining the top research priorities, an index term and a minimum data set (core outcome set and core data elements set – core outcome set (COS)/core data elements (CDE)).Objective To describe how perspectives were gathered and report the detailed sampling characteristics.Methods A two-stage, electronic survey was used to gather and seek initial consensus. Perspectives were sought from spinal surgeons, other healthcare professionals and people with degenerative cervical myelopathy (DCM). Participants were allocated to one of two parallel streams: (1) priority setting or (2) minimum dataset. An email campaign was developed to advertise the survey to relevant global stakeholder individuals and organisations. People with DCM were recruited using the international DCM charity Myelopathy.organd its social media channels. A network of global partners was recruited to act as project ambassadors. Data from Google Analytics, MailChimp and Calibrum helped optimise survey dissemination.Results Survey engagement was high amongst the three stakeholder groups: 208 people with DCM, 389 spinal surgeons and 157 other healthcare professionals. Individuals from 76 different countries participated; the United States, United Kingdom and Canada were the most common countries of participants.Conclusion AO Spine RECODE-DCM recruited a diverse and sufficient number of participants for an international PSP and COS/CDE process. Whilst PSP and COS/CDE have been undertaken in other fields, to our knowledge, this is the first time they have been combined in one process.

Published
2022
Full Text
View/download PDF

48. Gathering Global Perspectives to Establish the Research Priorities and Minimum Data Sets for Degenerative Cervical Myelopathy: Sampling Strategy of the First Round Consensus Surveys of AO Spine RECODE-DCM.

Author

Mowforth, Oliver D., Khan, Danyal Z, Wong, Mei Yin, Pickering, George A. E., Dean, Lydia, Magee, Joe, Mullarkey, Laura, Hirayama, Yuri, Rihova, Martina, Butler, Max, Stewart, Max, Goulson, Beth, Ahmed, Shahzaib, Fricke, Kai, Popa-Nimigean, Vladimir, Millar, Zack, Venkatesh, Ashwin, Willison, Alice, Senthil, Keerthi, and Hazenbiller, Olesja

Published
2022
Full Text
View/download PDF

49. Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma.

Author

Birch, Joanna L., Coull, Barry J., Spender, Lindsay C., Watt, Courtney, Willison, Alice, Syed, Nelofer, Chalmers, Anthony J., Hossain-Ibrahim, M. Kismet, and Inman, Gareth J.

Subjects
*TRANSFORMING growth factors-beta, *BRAIN tumors, *GLIOBLASTOMA multiforme
Abstract

Glioblastoma (GBM) is an aggressive and devastating primary brain cancer which responds very poorly to treatment. The average survival time of patients is only 14–15 months from diagnosis so there is a clear and unmet need for the development of novel targeted therapies to improve patient outcomes. The multifunctional cytokine TGFβ plays fundamental roles in development, adult tissue homeostasis, tissue wound repair and immune responses. Dysfunction of TGFβ signalling has been implicated in both the development and progression of many tumour types including GBM, thereby potentially providing an actionable target for its treatment. This review will examine TGFβ signalling mechanisms and their role in the development and progression of GBM. The targeting of TGFβ signalling using a variety of approaches including the TGFβ binding protein Decorin will be highlighted as attractive therapeutic strategies. • TGFβ can act as a context dependent tumour suppressor and tumour promoter in GBM. • TGFβ can modulate GBM tumour cell proliferation, migration, invasion and stemness. • TGFβ can modulate the tumour microenvironment in GBM. • TGFβ signalling is a promising target for therapeutic intervention for some GBM. • DCN may have therapeutic potential in GBM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.

Author

Pfeuffer S, Rolfes L, Ingwersen J, Pul R, Kleinschnitz K, Korsen M, Räuber S, Ruck T, Schieferdecker S, Willison AG, Aktas O, Kleinschnitz C, Hartung HP, Kappos L, and Meuth SG

Subjects
Humans, Male, United States, Adult, Female, Prospective Studies, Treatment Outcome, Antilymphocyte Serum, Recurrence, Multiple Sclerosis, Relapsing-Remitting drug therapy, Multiple Sclerosis drug therapy
Abstract

Background and Objectives: B cell-depleting antibodies were proven as effective strategy for the treatment of relapsing multiple sclerosis (RMS). The monoclonal antibody ocrelizumab was approved in 2017 in the United States and in 2018 in the European Union, but despite proven efficacy in randomized, controlled clinical trials, its effectiveness in the real-world setting remains to be fully elucidated. In particular, most study patients were treatment naive or switched from injectable therapies, whereas oral substances or monoclonal antibodies made up >1% of previous treatments., Methods: We evaluated ocrelizumab-treated patients with RMS enrolled in the prospective cohorts at the University Hospitals Duesseldorf and Essen, Germany. Epidemiologic data at baseline were compared, and Cox proportional hazard models were applied to evaluate outcomes., Results: Two hundred eighty patients were included (median age: 37 years, 35% male patients). Compared with using ocrelizumab as a first-line treatment, its use as a third-line therapy increased hazard ratios (HRs) for relapse and disability progression, whereas differences between first- vs second-line and second- vs third-line remained smaller. We stratified patients according to their last previous disease-modifying treatment and here identified fingolimod (FTY) (45 patients, median age 40 years, 33% male patients) as a relevant risk factor for ongoing relapse activity despite 2nd-line (HR: 3.417 [1.007-11.600]) or 3rd-line (HR: 5.903 [2.489-13.999]) ocrelizumab treatment, disability worsening (2nd line: HR: 3.571 [1.013-12.589]; 3rd line: HR: 4.502 [1.728-11.729]), and occurrence of new/enlarging MRI lesions (2nd line: HR: 1.939 [0.604-6.228]; 3rd line: HR: 4.627 [1.982-10.802]). Effects were persistent throughout the whole follow-up. Neither peripheral B-cell repopulation nor immunoglobulin G levels were associated with rekindling disease activity., Discussion: Our prospectively collected observational data suggest suboptimal effectiveness of ocrelizumab in patients switching from FTY compared with those switching from other substances or having been treatment naive. These findings support previous studies indicating abated effectiveness of immune cell-depleting therapies following FTY treatment in patients with RMS., Classification of Evidence: This study provides Class IV evidence that for patients with RMS, previous treatment with FTY compared with previous treatment with other immunomodulating therapies decreases the effectiveness of ocrelizumab., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results